Related Experiment Video
Updated: Jul 4, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II
Benjamin Stieglitz1, Christine Bee, Daniel Schwarz
1Physikalische Chemie 1, Fakultät für Chemie und Biochemie, Ruhr-Universität Bochum, Bochum, Germany.
Abstract:
A class of putative Ras effectors called Ras association domain family (RASSF) represents non-enzymatic adaptors that were shown to be important in tumour suppression. RASSF5, a member of this family, exists in two splice variants known as NORE1A and RAPL. Both of them are involved in distinct cellular pathways triggered by Ras and Rap, respectively. Here we describe the crystal structure of Ras in complex with the Ras binding domain (RBD) of NORE1A/RAPL. All Ras effectors share a common topology in their RBD creating an interface with the switch I region of Ras, whereas NORE1A/RAPL RBD reveals additional structural elements forming a unique Ras switch II binding site. Consequently, the contact area of NORE1A is extended as compared with other Ras effectors. We demonstrate that the enlarged interface provides a rationale for an exceptionally long lifetime of the complex. This is a specific attribute characterizing the effector function of NORE1A/RAPL as adaptors, in contrast to classical enzymatic effectors such as Raf, RalGDS or PI3K, which are known to form highly dynamic short-lived complexes with Ras.
Insights
Ras association domain family (RASSF) proteins are crucial for tumor suppression. Researchers elucidated the crystal structure of Ras bound to RASSF5 variants NORE1A/RAPL, revealing an extended interface that enhances complex stability.
Area of Science:
- Molecular Biology
- Structural Biology
- Cancer Research
Background:
- Ras association domain family (RASSF) proteins are key non-enzymatic adaptors involved in tumor suppression.
- RASSF5, a member of this family, has two splice variants, NORE1A and RAPL, which mediate distinct cellular pathways.
- These variants are activated by Ras and Rap signaling, respectively.
Purpose of the Study:
- To determine the crystal structure of Ras in complex with the Ras binding domain (RBD) of NORE1A/RAPL.
- To understand the structural basis for the interaction between Ras and NORE1A/RAPL.
- To compare the binding characteristics of NORE1A/RAPL with other Ras effectors.
Main Methods:
- X-ray crystallography to determine the structure of the Ras-RBD complex.
- Structural analysis to identify key interaction interfaces.
- Comparison of structural data with known Ras effector interactions.
Main Results:
- The crystal structure of Ras bound to the NORE1A/RAPL RBD was determined.
- NORE1A/RAPL RBD possesses unique structural elements that create an extended binding interface with Ras, including a novel Ras switch II binding site.
- This enlarged interface leads to a significantly longer complex lifetime compared to enzymatic Ras effectors.
Conclusions:
- The unique structural features of NORE1A/RAPL RBD explain their prolonged interaction with Ras.
- This extended complex stability is a defining characteristic of NORE1A/RAPL as adaptors, differentiating them from transient enzymatic Ras effectors.
- The findings provide insights into the distinct mechanisms of Ras signal transduction mediated by different effector families.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Abnormal Proliferation
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
The Ras Gene
Ras is a superfamily...
